Biogen lifts full-year outlook amid Alzheimer’s drug strength, sending shares up

Published 31/07/2025, 11:22
© Reuters.

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted better-than-anticipated first-quarter revenue and raised its full-year guidance thanks in part to solid sales of its Alzheimer’s drug.

U.S. sales of its Leqembi medicine, which competes with Eli Lilly (NYSE:LLY)’s Kisunla in the market for drugs that can help clear the sticky clumps of protein that are believed to be affiliated with Alzheimer’s, came in at approximately $63 million. This would represent sequential growth of 20%.

Globally, in-market sales of Leqembi were $160 million, factoring a boost from in a one-time shipment to China.

Biogen said it has also seen "resilience" in its multiple sclerosis business, driven by demand for its Vumerity medication. While the multiple sclerosis unit is still a key source of revenue for the company, it has faced recent headwinds from weakening demand linked to intensifying competition.

As a result, Leqembi has become an increasingly crucial portion of Biogen’s results, with the drug seen as a tool to help it diversify its offerings and transform its portfolio.

Against this backdrop, Biogen lifted its estimates for adjusted diluted earnings per share to between $15.50 to $16.00, up from a prior estimate of $14.50 to $15.50. Total (EPA:TTEF) revenue is seen flat year-over-year, an improvement from an earlier outlook for a mid-single digit decline.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.